Gilead Sciences Inc logo

GILD - Gilead Sciences Inc Share Price

$62.98 -0.2  -0.3%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £61.25bn
Enterprise Value £62.69bn
Revenue £17.19bn
Position in Universe 130th / 6410
Bullish
Bearish
Unlock GILD Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GILD Revenue Unlock GILD Revenue

Net Income

GILD Net Income Unlock GILD Revenue

Normalised EPS

GILD Normalised EPS Unlock GILD Revenue

PE Ratio Range

GILD PE Ratio Range Unlock GILD Revenue

Dividend Yield Range

GILD Dividend Yield Range Unlock GILD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GILD EPS Forecasts Unlock GILD Revenue
Profile Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated June 22, 1987
Public Since January 1, 1992
No. of Shareholders: 375
No. of Employees: 11,000
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Global 100, Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 1,265,145,612
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GILD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GILD
Upcoming Events for GILD
Similar to GILD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.